Melfalanhydrochloride Teva

Melphalan Hydrochloride, the active ingredient in Melfalanhydrochloride Teva, is an alkylating agent presented as a sterile injectable solution for intravenous use. It is employed in the treatment of certain cancers such as multiple myeloma, ovarian cancer and malignant melanoma. GNH USA supplies Melfalanhydrochloride Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Melphalan Hydrochloride is an alkylating chemotherapy agent used in the treatment of specific hematologic and solid tumours.

- Multiple myeloma: reduces malignant plasma cells and prolongs patient survival. - Ovarian cancer: incorporated into combination regimens to target ovarian tumour cells. - Malignant melanoma: employed in high‑dose protocols for metastatic melanoma.

Melphalan Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during treatment. - Bone marrow suppression: decreased blood cell counts leading to anemia or infection risk. - Fatigue: persistent tiredness experienced by many patients. - Alopecia: hair loss occurring during therapy.

Serious or Rare Side Effects: - Severe neutropenia: marked reduction in neutrophils increasing infection risk. - Pulmonary toxicity: rare lung inflammation that may impair breathing. - Secondary malignancies: possible development of new cancers after treatment.

When using melphalan, careful monitoring and specific precautions are recommended.

- Monitor blood counts: regular CBCs to detect marrow suppression. - Assess renal function: adjust therapy if kidney impairment is present. - Evaluate hepatic function: liver disease may affect drug metabolism. - Avoid in patients with known hypersensitivity to nitrogen‑mustard agents. - Use effective contraception: teratogenic risk requires pregnancy prevention. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Melphalan can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Live vaccines: may cause severe infection in immunocompromised patients. - Myelosuppressive agents: additive bone‑marrow toxicity can be dangerous. - CYP450 inducers: may reduce melphalan exposure and efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased risk of bleeding. - NSAIDs: may exacerbate gastrointestinal toxicity. - Renal excretion competitors: can alter melphalan clearance and plasma levels.